Αρχική World News FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer World News FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Από Ogkologos - 13 Μαΐου, 2026 312 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Pesticide Usage, in Particular of Picloram, Associated with Early Onset Colorectal... 4 Μαΐου, 2026 Vitamin D Supplements Don’t Reduce Cancer Incidence, Trial Shows 13 Δεκεμβρίου, 2018 Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab... 9 Ιουλίου, 2021 COVID-19 Takes the Life of a Widowed Mother of 6 Who... 20 Μαρτίου, 2020 Φόρτωση περισσοτέρων HOT NEWS ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy... Patient Guide on Immunotherapy Side Effects and Their Management Now Available... EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan